Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01046422 · ClinicalTrials.gov registry record · Phase 2

Safety Study of BMS-770767 in Subjects With Type 2 Diabetes

A Phase 2 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
76
Enrollment target

NCT01046422: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.

NCT01046422 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 76 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01046422, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
76 participants
Enrollment target

Study Summary

The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population

Interventions

  • DRUG Placebo
  • DRUG BMS-770767

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2010-05
Est. Completion 2011-01
Phase Phase 2
Bristol-Myers Squibb

1,025 total trials

What the finished NCT01046422 record still lists

NCT01046422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (43% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01046422 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01046422 about?

NCT01046422 is a clinical study titled "Safety Study of BMS-770767 in Subjects With Type 2 Diabetes". The purpose of this study is to determine if BMS-770767 is safe, well tolerated, measure its levels in the blood (pharmacokinetics), and measure the levels of chemicals (biomarkers) that may be affected by this drug (pharmacodynamics) in a type 2 diabetes patient population

What is the current status of trial NCT01046422?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2010-05. Estimated completion is 2011-01.

What interventions are being tested in trial NCT01046422?

The interventions under investigation include: Placebo (DRUG), BMS-770767 (DRUG).

Who is sponsoring clinical trial NCT01046422?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01046422's enrollment target sits among peer trials

76 893rd of 2000 higher than 1,101 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02615184 · 76 participants · Phase 2

    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

  • NCT02821741 · 76 participants · NA

    Effects of External Ear Stimulation on Pain Perception and Mood

  • NCT03019757 · 76 participants

    Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

  • NCT03353584 · 76 participants · NA

    Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01046422, the US trial registry maintained by the National Library of Medicine. NCT01046422 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.